Cargando…

Coronary Flow Evaluation in Heart Transplant Patients Compared to Healthy Controls Documents the Superiority of Coronary Flow Velocity Reserve Companion as Diagnostic and Prognostic Tool

BACKGROUND: Distinct contributions by functional or structural alterations of coronary microcirculation in heart transplantation (HT) and their prognostic role have not been fully elucidated. We aimed to identify the mechanisms of coronary microvascular dysfunction (CMD) in HT and their prognostic i...

Descripción completa

Detalles Bibliográficos
Autores principales: Cecere, Annagrazia, Kerkhof, Peter L. M., Civieri, Giovanni, Angelini, Annalisa, Gambino, Antonio, Fraiese, Angela, Bottio, Tomaso, Osto, Elena, Famoso, Giulia, Fedrigo, Marny, Giacomin, Enrico, Toscano, Giuseppe, Montisci, Roberta, Iliceto, Sabino, Gerosa, Gino, Tona, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263115/
https://www.ncbi.nlm.nih.gov/pubmed/35811712
http://dx.doi.org/10.3389/fcvm.2022.887370
_version_ 1784742654843551744
author Cecere, Annagrazia
Kerkhof, Peter L. M.
Civieri, Giovanni
Angelini, Annalisa
Gambino, Antonio
Fraiese, Angela
Bottio, Tomaso
Osto, Elena
Famoso, Giulia
Fedrigo, Marny
Giacomin, Enrico
Toscano, Giuseppe
Montisci, Roberta
Iliceto, Sabino
Gerosa, Gino
Tona, Francesco
author_facet Cecere, Annagrazia
Kerkhof, Peter L. M.
Civieri, Giovanni
Angelini, Annalisa
Gambino, Antonio
Fraiese, Angela
Bottio, Tomaso
Osto, Elena
Famoso, Giulia
Fedrigo, Marny
Giacomin, Enrico
Toscano, Giuseppe
Montisci, Roberta
Iliceto, Sabino
Gerosa, Gino
Tona, Francesco
author_sort Cecere, Annagrazia
collection PubMed
description BACKGROUND: Distinct contributions by functional or structural alterations of coronary microcirculation in heart transplantation (HT) and their prognostic role have not been fully elucidated. We aimed to identify the mechanisms of coronary microvascular dysfunction (CMD) in HT and their prognostic implications. METHODS: 134 patients, surviving at least 5 years after HT, without evidence of angiographic vasculopathy or symptoms/signs of rejection were included. 50 healthy volunteers served as controls. All underwent the assessment of rest and hyperemic coronary diastolic peak flow velocity (DPV(r) and DPV(h)) and coronary flow velocity reserve (CFVR) and its inherent companion that is based on the adjusted quadratic mean: CCFVR = √{(DPV(r))(2) + (DPV(h))(2)}. Additionally, basal and hyperemic coronary microvascular resistance (BMR and HMR) were estimated. RESULTS: Based on CFVR and DPV(h), HT patients can be assigned to four endotypes: endotype 1, discordant with preserved CFVR (3.1 ± 0.4); endotype 2, concordant with preserved CFVR (3.4 ± 0.5); endotype 3, concordant with impaired CFVR (1.8 ± 0.3) and endotype 4, discordant with impaired CFVR (2.0 ± 0.2). Intriguingly, endotype 1 showed lower DPV(r) (p < 0.0001) and lower DPV(h) (p < 0.0001) than controls with lower CFVR (p < 0.0001) and lower CCFVR (p < 0.0001) than controls. Moreover, both BMR and HMR were higher in endotype 1 than in controls (p = 0.001 and p < 0.0001, respectively), suggesting structural microvascular remodeling. Conversely, endotype 2 was comparable to controls. A 13/32 (41%) patients in endotype 1 died in a follow up of 28 years and mortality rate was comparable to endotype 3 (14/31, 45%). However, CCFVR was < 80 cm/s in all 13 deaths of endotype 1 (characterized by preserved CFVR). At multivariable analysis, CMD, DPVh < 75 cm/s and CCFVR < 80 cm/s were independent predictors of mortality. The inclusion of CCFVR < 80 cm/s to models with clinical indicators of mortality better predicted survival, compared to only adding CMD or DPV(h) < 75 cm/s (p < 0.0001 and p = 0.03, respectively). CONCLUSION: A normal CFVR could hide detection of microvasculopathy with high flow resistance and low flow velocities at rest. This microvasculopathy seems to be secondary to factors unrelated to HT (less rejections and more often diabetes). The combined use of CFVR and CCFVR provides more complete clinical and prognostic information on coronary microvasculopathy in HT.
format Online
Article
Text
id pubmed-9263115
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92631152022-07-09 Coronary Flow Evaluation in Heart Transplant Patients Compared to Healthy Controls Documents the Superiority of Coronary Flow Velocity Reserve Companion as Diagnostic and Prognostic Tool Cecere, Annagrazia Kerkhof, Peter L. M. Civieri, Giovanni Angelini, Annalisa Gambino, Antonio Fraiese, Angela Bottio, Tomaso Osto, Elena Famoso, Giulia Fedrigo, Marny Giacomin, Enrico Toscano, Giuseppe Montisci, Roberta Iliceto, Sabino Gerosa, Gino Tona, Francesco Front Cardiovasc Med Cardiovascular Medicine BACKGROUND: Distinct contributions by functional or structural alterations of coronary microcirculation in heart transplantation (HT) and their prognostic role have not been fully elucidated. We aimed to identify the mechanisms of coronary microvascular dysfunction (CMD) in HT and their prognostic implications. METHODS: 134 patients, surviving at least 5 years after HT, without evidence of angiographic vasculopathy or symptoms/signs of rejection were included. 50 healthy volunteers served as controls. All underwent the assessment of rest and hyperemic coronary diastolic peak flow velocity (DPV(r) and DPV(h)) and coronary flow velocity reserve (CFVR) and its inherent companion that is based on the adjusted quadratic mean: CCFVR = √{(DPV(r))(2) + (DPV(h))(2)}. Additionally, basal and hyperemic coronary microvascular resistance (BMR and HMR) were estimated. RESULTS: Based on CFVR and DPV(h), HT patients can be assigned to four endotypes: endotype 1, discordant with preserved CFVR (3.1 ± 0.4); endotype 2, concordant with preserved CFVR (3.4 ± 0.5); endotype 3, concordant with impaired CFVR (1.8 ± 0.3) and endotype 4, discordant with impaired CFVR (2.0 ± 0.2). Intriguingly, endotype 1 showed lower DPV(r) (p < 0.0001) and lower DPV(h) (p < 0.0001) than controls with lower CFVR (p < 0.0001) and lower CCFVR (p < 0.0001) than controls. Moreover, both BMR and HMR were higher in endotype 1 than in controls (p = 0.001 and p < 0.0001, respectively), suggesting structural microvascular remodeling. Conversely, endotype 2 was comparable to controls. A 13/32 (41%) patients in endotype 1 died in a follow up of 28 years and mortality rate was comparable to endotype 3 (14/31, 45%). However, CCFVR was < 80 cm/s in all 13 deaths of endotype 1 (characterized by preserved CFVR). At multivariable analysis, CMD, DPVh < 75 cm/s and CCFVR < 80 cm/s were independent predictors of mortality. The inclusion of CCFVR < 80 cm/s to models with clinical indicators of mortality better predicted survival, compared to only adding CMD or DPV(h) < 75 cm/s (p < 0.0001 and p = 0.03, respectively). CONCLUSION: A normal CFVR could hide detection of microvasculopathy with high flow resistance and low flow velocities at rest. This microvasculopathy seems to be secondary to factors unrelated to HT (less rejections and more often diabetes). The combined use of CFVR and CCFVR provides more complete clinical and prognostic information on coronary microvasculopathy in HT. Frontiers Media S.A. 2022-06-24 /pmc/articles/PMC9263115/ /pubmed/35811712 http://dx.doi.org/10.3389/fcvm.2022.887370 Text en Copyright © 2022 Cecere, Kerkhof, Civieri, Angelini, Gambino, Fraiese, Bottio, Osto, Famoso, Fedrigo, Giacomin, Toscano, Montisci, Iliceto, Gerosa and Tona. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Cecere, Annagrazia
Kerkhof, Peter L. M.
Civieri, Giovanni
Angelini, Annalisa
Gambino, Antonio
Fraiese, Angela
Bottio, Tomaso
Osto, Elena
Famoso, Giulia
Fedrigo, Marny
Giacomin, Enrico
Toscano, Giuseppe
Montisci, Roberta
Iliceto, Sabino
Gerosa, Gino
Tona, Francesco
Coronary Flow Evaluation in Heart Transplant Patients Compared to Healthy Controls Documents the Superiority of Coronary Flow Velocity Reserve Companion as Diagnostic and Prognostic Tool
title Coronary Flow Evaluation in Heart Transplant Patients Compared to Healthy Controls Documents the Superiority of Coronary Flow Velocity Reserve Companion as Diagnostic and Prognostic Tool
title_full Coronary Flow Evaluation in Heart Transplant Patients Compared to Healthy Controls Documents the Superiority of Coronary Flow Velocity Reserve Companion as Diagnostic and Prognostic Tool
title_fullStr Coronary Flow Evaluation in Heart Transplant Patients Compared to Healthy Controls Documents the Superiority of Coronary Flow Velocity Reserve Companion as Diagnostic and Prognostic Tool
title_full_unstemmed Coronary Flow Evaluation in Heart Transplant Patients Compared to Healthy Controls Documents the Superiority of Coronary Flow Velocity Reserve Companion as Diagnostic and Prognostic Tool
title_short Coronary Flow Evaluation in Heart Transplant Patients Compared to Healthy Controls Documents the Superiority of Coronary Flow Velocity Reserve Companion as Diagnostic and Prognostic Tool
title_sort coronary flow evaluation in heart transplant patients compared to healthy controls documents the superiority of coronary flow velocity reserve companion as diagnostic and prognostic tool
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263115/
https://www.ncbi.nlm.nih.gov/pubmed/35811712
http://dx.doi.org/10.3389/fcvm.2022.887370
work_keys_str_mv AT cecereannagrazia coronaryflowevaluationinhearttransplantpatientscomparedtohealthycontrolsdocumentsthesuperiorityofcoronaryflowvelocityreservecompanionasdiagnosticandprognostictool
AT kerkhofpeterlm coronaryflowevaluationinhearttransplantpatientscomparedtohealthycontrolsdocumentsthesuperiorityofcoronaryflowvelocityreservecompanionasdiagnosticandprognostictool
AT civierigiovanni coronaryflowevaluationinhearttransplantpatientscomparedtohealthycontrolsdocumentsthesuperiorityofcoronaryflowvelocityreservecompanionasdiagnosticandprognostictool
AT angeliniannalisa coronaryflowevaluationinhearttransplantpatientscomparedtohealthycontrolsdocumentsthesuperiorityofcoronaryflowvelocityreservecompanionasdiagnosticandprognostictool
AT gambinoantonio coronaryflowevaluationinhearttransplantpatientscomparedtohealthycontrolsdocumentsthesuperiorityofcoronaryflowvelocityreservecompanionasdiagnosticandprognostictool
AT fraieseangela coronaryflowevaluationinhearttransplantpatientscomparedtohealthycontrolsdocumentsthesuperiorityofcoronaryflowvelocityreservecompanionasdiagnosticandprognostictool
AT bottiotomaso coronaryflowevaluationinhearttransplantpatientscomparedtohealthycontrolsdocumentsthesuperiorityofcoronaryflowvelocityreservecompanionasdiagnosticandprognostictool
AT ostoelena coronaryflowevaluationinhearttransplantpatientscomparedtohealthycontrolsdocumentsthesuperiorityofcoronaryflowvelocityreservecompanionasdiagnosticandprognostictool
AT famosogiulia coronaryflowevaluationinhearttransplantpatientscomparedtohealthycontrolsdocumentsthesuperiorityofcoronaryflowvelocityreservecompanionasdiagnosticandprognostictool
AT fedrigomarny coronaryflowevaluationinhearttransplantpatientscomparedtohealthycontrolsdocumentsthesuperiorityofcoronaryflowvelocityreservecompanionasdiagnosticandprognostictool
AT giacominenrico coronaryflowevaluationinhearttransplantpatientscomparedtohealthycontrolsdocumentsthesuperiorityofcoronaryflowvelocityreservecompanionasdiagnosticandprognostictool
AT toscanogiuseppe coronaryflowevaluationinhearttransplantpatientscomparedtohealthycontrolsdocumentsthesuperiorityofcoronaryflowvelocityreservecompanionasdiagnosticandprognostictool
AT montisciroberta coronaryflowevaluationinhearttransplantpatientscomparedtohealthycontrolsdocumentsthesuperiorityofcoronaryflowvelocityreservecompanionasdiagnosticandprognostictool
AT ilicetosabino coronaryflowevaluationinhearttransplantpatientscomparedtohealthycontrolsdocumentsthesuperiorityofcoronaryflowvelocityreservecompanionasdiagnosticandprognostictool
AT gerosagino coronaryflowevaluationinhearttransplantpatientscomparedtohealthycontrolsdocumentsthesuperiorityofcoronaryflowvelocityreservecompanionasdiagnosticandprognostictool
AT tonafrancesco coronaryflowevaluationinhearttransplantpatientscomparedtohealthycontrolsdocumentsthesuperiorityofcoronaryflowvelocityreservecompanionasdiagnosticandprognostictool